Anderson Nathan, Gillman Andrea G, Wasan Ajay D
Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Pain Medicine, Pittsburgh, PA, USA.
J Pain Res. 2020 May 6;13:955-960. doi: 10.2147/JPR.S249592. eCollection 2020.
Xtampza ER (XER) is a long-acting oxycodone formulation which was designed to be abuse-deterrent and to overcome capsule-swallowing issues. This pilot study evaluated the effectiveness of XER at reducing swallowing difficulty while providing effective analgesia in the setting of chronic pain.
Eleven subjects with chronic pain who reported pill-swallowing difficulty were enrolled in a 6-week uncontrolled open-label pilot study in which their prescribed daily opioid medication was converted to XER. Swallowing difficulty, pain intensity, opioid satisfaction, and secondary indicators of pain response were recorded for subjects throughout the study.
Both swallowing difficulty and opioid satisfaction (XER vs baseline opioid) improved significantly over the 6-week study period ( < 0.05), while pain intensity ratings demonstrated no significant change. No significant change was noted in any of the secondary pain, mental health, or physical function measures after conversion to XER compared to baseline.
Subjects experienced improvement in both swallowing and opioid medication satisfaction after conversion to XER with no significant change in pain intensity and related measures.
Xtampza ER（XER）是一种长效羟考酮制剂，旨在具有抗滥用性并克服吞服胶囊的问题。这项初步研究评估了XER在减轻吞咽困难的同时，为慢性疼痛患者提供有效镇痛的效果。
11名报告有吞服药丸困难的慢性疼痛患者参加了一项为期6周的非对照开放标签初步研究，在该研究中，他们规定的每日阿片类药物被转换为XER。在整个研究过程中记录受试者的吞咽困难、疼痛强度、阿片类药物满意度以及疼痛反应的次要指标。
在为期6周的研究期间，吞咽困难和阿片类药物满意度（XER与基线阿片类药物相比）均有显著改善（<0.05），而疼痛强度评分无显著变化。与基线相比，转换为XER后，任何次要疼痛、心理健康或身体功能指标均未发现显著变化。
转换为XER后，受试者的吞咽和阿片类药物满意度均有所改善，疼痛强度及相关指标无显著变化。
